The NeurologyLive® headache and migraine clinical focus page offers information, podcasts, videos, and news and interviews with physicians related to the care of patients with headache disorders such as chronic and episodic migraine, cluster headache, tension-type headache, and more. The page includes updates on the latest FDA actions, clinical guidelines, and study and clinical trial findings.
August 29th 2025
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 29, 2025.
Effectiveness of Rimegepant Further Displayed in Pooled Phase 3 Analysis
September 23rd 2024Stewart Tepper, MD, Vice President at the New England Institute for Neurology and Headache in Stamford, Connecticut, provided commentary on a wide-scale analysis of nearly 5000 patients testing the effects of rimegepant.
FDA Clears Clearmind Biomedical’s Neuroblade System for Minimally Invasive Neurosurgery
September 3rd 2024The system is composed of the Neuroblade, a single-use multifunctional neuroendoscope; the Neuropad, a reusable medical-grade tablet; and Clearpath, a disposable transparent access sheath.
Heavy Metal and Trace Element Alterations Observed in Patients During a Migraine Attack
August 27th 2024A recent prospective study reveals significant alterations in heavy metal and trace element levels among patients with migraine, suggesting these imbalances may play a role in the pathogenesis and progression of the condition.
Migraine Not Directly Linked to Traditional Cardiovascular Disease Risk Factors
August 14th 2024The study suggests that overall, migraine is not directly related to traditional CVRFs, and further research is needed, especially in younger populations, to explore these relationships over longer periods.
Exploring AI-Powered Music Therapy as a Solution to Chronic Pain Management and the Opioid Crisis
August 6th 2024Neal K. Shah, CEO of CareYaya Health Technologies, explores the potential of AI-enhanced, neurotech-powered music therapy as a revolutionary solution to chronic pain management and the opioid crisis.
Nerivio Remote Electrical Neuromodulation Safe and Effective in Children With Migraine, Study Shows
August 6th 2024In pediatric patients, the average treatment intensity was 22.8% of the maximum stimulator intensity, with slightly lower intensity levels compared to previous studies in adolescents and adults.